Serum circ_DLGAP4, lncRNA KCNQ1OT1, and Their Targets by Erythropoietin Resistance in Chronic Kidney Disease

Plain-language summary

This study examines the relationship between erythropoietin resistance and molecular markers in the blood such as circ_DLGAP4 and lncRNA KCNQ1OT1 in patients with chronic kidney disease. It included adults over 18 with chronic kidney disease, some of whom were on dialysis. It was conducted as a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Ain Shams University

Start date

8/1/2024

Estimated completion

7/1/2025

Countries

Egypt

Related genes

Locations

• Cairo, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* adult patients (\> 18 years) with a final clinical diagnosis of CKD with a category G2-G5
* mild to severe albuminuria (A1-A3),
* patients with an eGFR \< 15 mL/min/1.73 m2 (kidney failure or ESKD) undergoing HD.

Exclusion Criteria:

* Subjects having \< 18 years of age,
* non-compliant persons,
* smokers,
* patients with low risk of CKD (category G1),
* kidney transplant recipients,
* individuals in critical conditions, those with acute kidney injury, ischemic heart disease, cancer, or those receiving chemotherapy, or having cognitive impairment